XResearch (XRES), A Crypto Investment Research Fund And Media Platform, Announces Token Holder Equity And Regulation S ICO In Q4 2018
Read about XResearch at www.xres.io
NEW YORK, Sept. 10, 2018 (GLOBE NEWSWIRE) -- XResearch (XRES), a cryptocurrency, blockchain startup, and ICO investment research fund and media portal, has just announced that its Regulation S* securities token offering (STO) will begin in Q4 2018.
What is XResearch?
XResearch is the world’s first crypto-, blockchain-, and ICO-focused investment research fund and media portal for institutional and retail investors around the world.
The team is building a crypto community commons for crypto investors worldwide by offering institutional-quality research services and content as well as a decentralized application (DApp) that allows XRES token holders to:
- Subscribe to institutional-quality research at a discounted rate
- Contribute independent analyses to the media platform, where contributions will be ranked by a network of validating nodes on metrics such as traffic and engagement
- Become verified contributors who can begin charging a subscription fee for their research, just like the core XResearch team
- Share in 5% of the equity of the company (all XRES tokenholders in aggregate)
The long-term vision of XResearch is to build a decentralized autonomous organization (DAO), that identifies, empowers, and incentivizes the best research talent worldwide to contribute to and participate in the XResearch ecosystem.
The Team Behind XResearch
XResearch is led by Mr. Charles Wyman, Chief Investment Officer and former Head of Global Credit Research at PIMCO. Mr. Wyman is joined by a veteran team of Wall Street analysts and investment professionals, including Principal Steven Wasserman, Senior Advisor to a $4 billion NYC-based hedge fund; Chief Operating Officer Barry Cohen, former Portfolio Manager in the GMI/Strategic Investment Group at Merrill Lynch; and Chief Blockchain Officer Neil Benedict, former Head of Product Development at BANKEX. Advisors to the team include Leonard Seelig, Executive Director of BABB and Serg Gulko, CEO of XTRD.
To learn more about XRES, join the Telegram community (https://t.me/XResearch ), follow them on Twitter @XResearchICO, connect with the team on LinkedIn (www.linkedin.com/company/xresearch ), or email email@example.com .
*XRES Tokens will only be offered by XResearch, Crypto Online Media to non-US persons in compliance with the registration provided by Regulation D and Regulation S of the United States Securities Exchange Act.
About XResearch, Crypto Online Media
XResearch, Crypto Online Media is a decentralized cryptocurrency, blockchain startup, and ICO investment research firm and media portal for investors worldwide. By decentralizing investment research content, XResearch seeks to identify, empower, and incentivize the best research talent worldwide to contribute independent analyses to the XResearch crypto community commons. All XRES token holders will, in aggregate, own 5% equity in the company.
Charles Wyman, Chief Investment Officer firstname.lastname@example.org
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Dubai Airports19.2.2019 15:47:45 | Pressemeddelelse
Dubai Airports partners with XDubai for one-of-a-kind stunt embodying Dubai’s ambitious spirit
PubMatic, Inc.19.2.2019 15:01:30 | Pressemeddelelse
New PubMatic Research Finds Mobile In-App Monetization Spurred by Video and Header Bidding, Though Challenges Remain
VistaJet Ltd19.2.2019 11:35:28 | Pressemeddelelse
VistaJet Partners With Scuderia Ferrari Mission Winnow for the 2019 Formula One World Championship
Association of Corporate Counsel19.2.2019 11:01:16 | Pressemeddelelse
ACC Opens New Europe Headquarters in Brussels
Centrient Pharmaceuticals19.2.2019 09:01:40 | Pressemeddelelse
The Delhi High Court in India has issued an injunction, restraining Sinopharm Weiqida from exporting its “Amoxycillin Trihydrate” product to India, as it infringes the patent of Centrient Pharmaceuticals
Cansativa GmbH19.2.2019 07:16:08 | Pressemeddelelse
New Milestone for Cansativa Towards “EU GxP Innovation Hub”
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum